A previous observational clinical study showed that the administration of renin‐angiotensin‐aldosterone system inhibitors (RASi), including AT1‐RB, was associated with an approximately 30% lower risk of hospital admission due to any fracture among patients with secondary hyperparathyroidism undergoing hemodialysis.(18) The effect of RASi on preventing fractures in patients with CKD seemed more evident than that in the general population;(19) however, the reason behind this finding remains unknown. Here, AGTR1 is linked to chronic kidney disease.